Evestra’s R&D Targets:
Evestra, Inc. is a privately held biopharmaceutical company developing innovative products in women’s healthcare and first-in-class oncology asset based on innovative steroid medicinal chemistry and vaginal drug delivery technology. Evestra’s product pipeline includes pre-clinical and clinical-stage products.
Based in San Antonio and Schertz, Texas, Evestra has more than ten years of experience in biopharmaceutical research and development.
At Evestra, we aim to contribute to the health and well-being of women throughout the world through the discovery, development, and commercialization of innovative, next-generation women’s healthcare technologies and products that address unmet needs.
Intelligent solutions are at the core of what we do. Evestra’s goal is to build a better tomorrow for women, everywhere. Through purpose-driven methods, the latest medical research, and transformative technology, we strive to improve the lives of hundreds of millions of women.
Evestra’s proprietary products are based on two enabling technologies, these are medicinal chemistry and vaginal ring technology. Both technologies are supported by GMP manufacturing of APIs and Drug Products. Evestra’s product pipeline includes pre-clinical products and clinical-stage products, and all Evestra products are protected by broad US and international issued patents.
We are proud of our partnership with Evestra Onkologia and the European Regional Development Fund grant.
Evestra Onkologia is a Polish biopharmaceutical start-up company located in Lodz, launched by Evestra, Inc. A distinguished team leads them with an impressive record in developing and commercializing innovative oncology and other proliferative diseases products.
To accomplish its core mission, Evestra Onkologia will continue to establish various fruitful collaborations with leading Polish research institutions and for-profit CRO companies to enhance the development and commercialization of its innovative assets.
Read selected news articles about Evestra, our ongoing work, and our future projects.
SAN ANTONIO (September 6, 2022) – The Mays Cancer Center at UT Health San Antonio and a local partner have been awarded a five-year, $3.3 million Academic Industry Partnership grant from the National Institutes of Health (NIH). It is the…
In November 2020, Evestra, Inc. received a grant from the Bill and Melinda Gates Foundation to develop a twice-yearly injectable contraceptive. The goal of this project is to enable greater access to modern contraceptives for…
SCHERTZ, Texas – Evestra, Inc. this week European partner Gedeon Richter becomes equity shareholder as the company celebrates 10 years.
Evestra is a biopharmaceutical company with an innovative product pipeline and mission to improve women’s health. Become a part of a world-class team that specializes in drug development here at Evestra.
